Archive

Dive into a collection of past posts and rediscover timeless content.

Salesforce Just Triggered a Powerful Buy Signal for 2026

Dec 24, 2025

•

3 min read

Salesforce Just Triggered a Powerful Buy Signal for 2026

A multi-timeframe moving-average crossover — with Golden Cross potential — and a defended $225 base suggest CRM could be primed for a 2026 breakout. Analyst upgrades and institutional buying add momentum to the rally thesis.

Amazon Now Delivery Push Could Boost Its 2026 Outlook

Dec 23, 2025

•

3 min read

Amazon Now Delivery Push Could Boost Its 2026 Outlook

Aiming for near-instant urban delivery, Amazon Now looks to drive spontaneous purchases and deepen Prime engagement. Analysts say if it scales without hurting margins, the service could be the catalyst that breaks AMZN out into 2026.

2 Stocks to Avoid as Crypto Momentum Wanes

Dec 22, 2025

•

3 min read

2 Stocks to Avoid as Crypto Momentum Wanes

With Bitcoin losing steam and regulatory clarity still off in the distance, crypto-linked names like SharpLink Gaming and TeraWulf face rising valuation and debt risks. Avoid these stocks until market momentum or clearer rules return.

Is Tesla Overvalued? 2 Reasons It Might Be a Bargain

Dec 21, 2025

•

3 min read

Is Tesla Overvalued? 2 Reasons It Might Be a Bargain

A triple‐digit P/E may look frothy, but a momentum-fueled breakout and strong analyst price targets suggest this rally could have more upside.

Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500

Dec 20, 2025

•

3 min read

Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500

Shares plunged 20% after earnings, but several Wall Street analysts raised targets to $500, implying more than 50% upside. Their bullish calls hinge on Broadcom’s AI-driven cash flow and a market-analyst disconnect over the sell-off.

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?

Dec 19, 2025

•

1 min read

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?

A possible move to reschedule marijuana to Schedule III could lift banking, tax and institutional barriers — unlocking capital that might fuel a major reversal. Still, support is tepid and retail-driven volatility means gains will depend on concrete policy and market catalysts.

Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.

Dec 18, 2025

•

3 min read

Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.

Paramount Skydance’s $30 all‐cash hostile bid upends Netflix’s cash‐and‐stock agreement, reigniting a potential bidding war. Antitrust scrutiny and shareholder votes are now likely to decide the winner.

Pfizer Adds to Its Big Bet on Weight Loss Drugs

Dec 17, 2025

•

3 min read

Pfizer Adds to Its Big Bet on Weight Loss Drugs

With a $2.1 billion licensing deal and a recent $10 billion buyout, Pfizer is doubling down on GLP‐1 pills and combo therapies to recoup waning COVID‐vaccine revenue.

3 Underrated Robotics Stocks Poised for Huge Gains

Dec 16, 2025

•

3 min read

3 Underrated Robotics Stocks Poised for Huge Gains

Small-cap robotics plays — Stereotaxis, Knightscope, and PROCEPT — with FDA approvals, new product rollouts, and improving production that could trigger significant upside. High-risk, under-the-radar opportunities for investors willing to look beyond the AI giants.

2 Small-Cap Biotechs That Could Reward Patient Investors

Dec 15, 2025

•

3 min read

2 Small-Cap Biotechs That Could Reward Patient Investors

Two speculative micro-cap plays — Mainz Biomed’s commercial cancer screen and NanoViricides’ novel antiviral platform — that could deliver outsized returns for investors willing to weather high risk and long timelines.

Archive

Dive into a collection of past posts and rediscover timeless content.

Salesforce Just Triggered a Powerful Buy Signal for 2026

Amazon Now Delivery Push Could Boost Its 2026 Outlook

2 Stocks to Avoid as Crypto Momentum Wanes

Is Tesla Overvalued? 2 Reasons It Might Be a Bargain

Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?

Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.

Pfizer Adds to Its Big Bet on Weight Loss Drugs

3 Underrated Robotics Stocks Poised for Huge Gains

2 Small-Cap Biotechs That Could Reward Patient Investors

The Markets Daily